REG - Genflow Biosciences - Non-Dilutive Grant Research Award

Genflow BiosciencesAnnouncement

11/10/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221011:nRSK4141Ca&default-theme=true

RNS Number : 4141C  Genflow Biosciences PLC  11 October 2022

PRESS RELEASE

11 October 2022

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Genflow Research Programme conducted with IVEX Lab Receives Non-Dilutive Grant
Worth Quarter of a Million Euros from Enterprise Estonia

 

Genflow (LSE: GENF) is pleased to announce that its adeno-associated virus
("AAV") research and development programme in Estonia, operated in
collaboration with IVEX lab OÜ ("IVEX"), an Estonian company specialising in
the research and development of biotechnology therapeutics, has received a
non-dilutive grant award of €250,000 from the Applied Research Programme of
Enterprise Estonia, an Estonian governmental institution designed to stimulate
business growth in the country.

The research and development programme is a collaborative project between
Genflow and IVEX focused on the development of an anti-aging gene therapy
platform designed to target nearly 100 million patients worldwide who suffer
from Werner's syndrome, non-alcoholic fatty liver disease ("NAFLD"), and
non-alcoholic steatohepatitis, an advanced form of NAFLD, as well as other
major clinical disorders.

IVEX, which is a leading biotech that has partnered with the largest
universities in Estonia: Tallinn University of Technology and University of
Tartu, is a strategic partner for Genflow. In April 2021, Genflow BE entered
into a collaborative research agreement with IVEX to optimise the design of
AAV vector delivery methods for anti-aging therapies based on Sirtuin-6, a
gene variant that is found in centenarians shown to have significant
capabilities to repair DNA damage contributing to aging, and for the
large-scale production of AAV vectors for in vivo study in animal models.

As part of the funded programme, Genflow and IVEX intend to create precise
tools to evaluate the effect of Genflow's gene therapy drug candidates at
unseen resolutions and precision levels which will likely optimise gene
delivery and improve gene therapies.

Additionally, the Company envisions that the anti-aging gene therapy platform
being developed promises a significant reduction of animal studies and will
determine the optimal drug dose and formulation prior to the start of clinical
trials. Furthermore, the project will seek to develop a series of alternative
novel gene therapy platforms in collaboration with the University of Tartu for
the precise delivery of a candidate drug. The initial results are anticipated
to be released in Q3 2023.

The Company believes that the non-dilutive grant received by IVEX from
Enterprise Estonia will support the acceleration of the project's development
of anti-aging gene therapies and expedite Genflow's drug development
programme.

Genflow is a UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and diseases
associated with advanced age.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are delighted and honored
by the Estonian government's decision to award this grant to the research
programme Genflow is conducting in collaboration with IVEX Lab. The grant will
enhance Genflow's future therapeutic developments and boost the Company's
pre-clinical drug discovery and research initiatives, aimed at assisting
people to live longer, healthier lives. I congratulate the Genflow team and
IVEX Lab for obtaining this encouraging financing, which confirms confidence
in the ant-aging science underpinning our business and our long-term goals."

Illar Pata, Chief Executive Officer and Owner of IVEX Lab OÜ, said: "Our
greatest asset in the field of gene therapy vehicle development is the clear
understanding about the specificity and efficiency of therapeutic gene
expression. The grant is supporting IVEX Lab OÜ to develop the preclinical
platform for the precise assessment of drug candidates and their therapeutic
performance."

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com/)

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKDBKKBDKQKD